Search

Displaying results 1251 - 1260 of 8575 in total
  1. Drug

    Isopropyl myristate

    go.drugbank.com/drugs/DB13966
    Approved

    Isopropyl myristate has been largely studied and impulsed as a skin penetration enhancer. … [A178078] At the moment the primary usage for which isopropyl myristate is formally indicated is as the active ingredient in a non-prescription pediculicide rinse [A32333, L1964, L1966].

  2. Drug

    Dorzolamide

    go.drugbank.com/drugs/DB00869
    ApprovedInvestigational

    [A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects. … [A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]

  3. Drug

    Beclamide

    go.drugbank.com/drugs/DB09011
    Experimental

    It was studied in the 1950s for generalised tonic-clonic seizures but was not effective for absence seizures.

  4. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency. … [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339]

  5. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK

  6. Drug

    Norgestimate

    go.drugbank.com/drugs/DB00957
    ApprovedInvestigational

    Norgestimate was first described in the literature in 1977. … [A191068] It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects.

  7. Drug

    Suprofen

    go.drugbank.com/drugs/DB00870
    ApprovedWithdrawn

    It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.

  8. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.

  9. Drug

    Latanoprost

    go.drugbank.com/drugs/DB00654
    ApprovedInvestigational

    [A184493] It has been found to be well-tolerated and its use does not normally result in systemic adverse effects like other drugs used to treat elevated intraocular pressure, such as [Timolol]. … It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment.

  10. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers.